Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Drugpatentwatch skyrizi biologic patent analysis?
Is guselkumab off patent in u s?
Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?
Lipitor vs generics what's the price gap?
When will latisse patent expire?

Oteseconazole fda approval?

See the DrugPatentWatch profile for Oteseconazole

Oteseconazole (VT-1161) is FDA-approved. In 2022, the FDA approved it for the treatment of recurrent vulvovaginal candidiasis (RVVC) in adult women who have a history of RVVC and who require long-term suppression therapy. It is an oral antifungal.

If you want:
- the exact approved dosing regimen and duration from the labeling,
- safety warnings and potential drug interactions, or
- how it’s used in clinical practice,

I can provide that as well. Do you want the specifics from the prescribing information or a quick summary?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

strong alternative

Brand Perception

Best Known For

FDA-approved for the treatment of recurrent vulvovaginal candidiasis (RVVC) in adult women who have a history of RVVC and who require long-term suppression therapy.

Core Claims

Oteseconazole (VT-1161) is FDA-approved.
FDA approved it in 2022 for recurrent vulvovaginal candidiasis (RVVC).
It is for adult women with a history of RVVC who require long-term suppression therapy.
It is an oral antifungal.

Differentiators

FDA-approved specifically for RVVC in adult women with a history of RVVC who require long-term suppression therapy.
Identified as VT-1161.

Pricing Perception: Not Mentioned